Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia

Paurnima Patil1 | Agata Cieslak2 | Stephan H. Bernhart3 | Umut H. Toprak4,5,6 | Rabea Wagener1,7 | Cristina López1,7 | Laura Wiehle1 | Susanne Bens1,7 | Janine Altmüller8 | Marek Franitza8 | Ingrid Scholz9 | Sandrine Jayne10 | Matthew J. Ahearn10 | Annika Scheffold11 | Billy M. C. Jebaraj11 | Christof Schneider11 | Dolors Costa12 | Martin J. S. Dyer10 | Peter Nürnberg8 | Jan Dürig14 | Patricia Johansson14 | Sebastian Böttcher15 | Matthias Schlesner4 | Marco Herling13 | Stephan Stilgenbauer11 | Elizabeth Macintyre2 | Reiner Siebert1,7

1Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany
2Diagnostic Haematology, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut national de recherche médicale (INSERM), Paris, France
3Interdisciplinary Center for Bioinformatics, Transcriptome Bioinformatics, University of Leipzig, Leipzig, Germany
4Bioinformatics and Omics Data Analytics, German Cancer Research Center, Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
5Division Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
6Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
7Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
8Cologne Center for Genomics, Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
9Omics IT and Data Management Core Facility, German Cancer Research Center, Heidelberg, Germany
10Ernest and Helen Scott Haematological Research Institute, Department of Cancer Studies, University of Leicester, Leicester, UK
11Department of Internal Medicine III, University of Ulm, Ulm, Germany
12Haematopathology Section, Hospital Clinic, Institut d’Investigaciones Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
13Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Ageing-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany
14Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
15Department III of Internal Medicine, University Hospital Rostock, Rostock, Germany

Correspondence
Reiner Siebert, Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Albert-Einstein-Allee 11, 89081 Ulm, Germany.
Email: reiner.siebert@uni-ulm.de

Funding information
Deutsche Forschungsgemeinschaft, Grant/Award Numbers: SFB 1074 (Project B9), SFB 1074 (Project B1), HE3553/4-2; Fritz Thyssen Foundation, Grant/Award Number: 10.15.2.034MN; Center for Molecular

Abstract
T-cell prolymphocytic leukemia (T-PLL) is an aggressive tumor with leukemic presentation of mature T-lymphocytes. Here, we aimed at characterizing the initial events in the molecular pathogenesis of T-PLL and particularly, at determining the point in T-cell differentiation when the hallmark oncogenic events, that is, inv(14)(q11q32)/t(14;14)(q11;q32) and t(X;14)(q28;q11) occur. To this end, we mined whole genome and transcriptome sequencing data of 17 and 11 T-PLL cases, respectively. Mapping of the 14q32.1 locus breakpoints identified only TCL1A, which was moreover

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2019 The Authors. Genes, Chromosomes and Cancer published by Wiley Periodicals LLC
T-cell prolymphocytic leukemia (T-PLL) is a rare T-cell leukemia affecting patients with an average age at diagnosis of 65 years. According to the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue, the postulated normal counterpart of the tumor cell in T-PLL is “an unknown T-cell with a mature (post-thymic) immunophenotype. Strong CD7 and co-expression of CD4 and CD8 and weak membrane CD3 may suggest that T-PLL arises from a T-cell at an intermediate stage of differentiation between cortical thymocytes and mature T lymphocytes.” Here, we challenged this postulate by using somatic genetic analyses rather than gene or protein expression data.

The genetic hallmark of T-PLL is an inv(14)(q11q32) or t(14;14) (q11;q32) involving the T-cell receptor (TCR) alpha/delta gene locus (TRA/TRD) at 14q11 and the TCR gene cluster at 14q32.1. Few T-PLL cases harbor an alternative translocation t(X;14)(q28;q11) involving TCL1A. Both the TCR/D-TCL1A and TCR/D-MTCP1 fusions are considered as disease initiating “primary” events in T-PLL. Translocations and inversions involving TCR loci are generally believed to result from aberrant V(D)J recombination events and lead to activation of oncogenes that are juxtaposed to the TCR locus enhancer elements. TCR rearrangements occur in a sequential and coordinated manner during both normal and leukemic T-cell development. Therefore, genomic characterization of TCR translocations can provide an insight into the timing of such oncogenic events.

To identify the cell in which the hallmark translocation/inversion involving TRA/TRD in T-PLL occurs, we investigated the genomic composition of the functional and illegitimate TRA/TRD rearrangements in a series of bona-fide T-PLL using an unbiased approach. In particular, we generated whole genome sequencing (WGS) data of 13 T-PLL cases and supplemented these with transcriptome sequencing (RNA-seq) of 11 of these 13 T-PLL cases. Moreover, we mined WGS data from four previously published cases of T-PLL. These four previously published cases also contained one of the 13 cases in which we herein independently generated WGS data (labeled as case #8 and #8a).

We performed WGS and RNA-seq in the cell line SUP-T11 previously shown to carry a TRA/TRD-TCL1A juxtaposition leading to TCL1A overexpression. This cell line has been reported to derive from a patient with T-ALL. Nevertheless, it lacks expression of markers for a precursor phenotype (TdT, CD34, CD1a) as well as of CD4, CD8 and TRG/D whereas other T-cell markers (sCD2, sCD3 and sCD7 and TRA/B) can be readily detected. These phenotypic data suggest that the diagnosis of T-PLL needs to be considered as differential to T-ALL (Supporting Information Figure 1). Thus, a total of 17 cases with WGS data entered the analyses (for details on patient cohort see Supporting Information Tables 1 and 2). In addition, to compare gene expression in T-PLL to normal peripheral T-cells, we performed RNA-seq on FAC-sorted CD4+ and CD8+ T-cell populations obtained from three separate blood donors each (Supporting Information Figure 2). The study was performed in agreement with the guidelines of the Institutional Review Boards of Christian-Albrecht-University Kiel (B295/11) and Ulm University (21/16).

Firstly, we focused on the architecture of illegitimate TRA/TRD rearrangements leading to the hallmark aberrations. Using WGS data we identified an inv(14)(q11q32) in 13/17 cases, t(14;14)(q11q32) in 3/17 cases (including SUP-T11) and t(X;14)(q28;q11) in 1/17 cases. We detected two breakpoints (one on the Watson and one on the Crick strand based on both derivatives/breakpoints) at the TRA/D locus and TCL1A/MTCP1 gene locus for all the cases (Figure 1A, 1B).
FIGURE 1  Oncogenic rearrangements in T-PLL and their effect on oncogene expression. A, Within the UCSC genome browser (GENCODE version 19), track bars indicate breakpoint locations at the 14q32 locus in T-PLL cases (n = 16 without case 13 with t(X;14)) and SUP-T11. Cases with inv(14) are indicated in red and cases with t(14;14) in blue (T-PLL Breakpoints track). B, Examples of Sanger sequences verifying inv(14), t(14;14) and t(X;14) fusion sequences in three T-PLL cases. The dotted lines mark the breakpoints. The N indicates the N-nucleotides inserted at the fusion junction of the sequences. C, Dot-plot showing the RNA expression values in fpkm (fragments per kilobase of transcript per million mapped reads) of TCL1A which is significantly higher expressed in seven T-PLL cases harboring inv(14) (red dots) and two T-PLL cases and SUP-T11 harboring t(14;14) (blue dots) as compared to benign CD4+ and CD8+ T-cells (n = 6) (black dots) \( P = 0.001 \), Mann-Whitney test). D, Schematic representation of differentiation stages of the physiological thymocyte development in humans and of the proposed thymocyte development in T-PLL. Stages in which the TRD, TRG, TRB and TRA rearrangements occur are indicated by arrows. The stages at which TCL1A and RAG genes are expressed physiologically in normal T-cells and aberrantly after the occurrence of hallmark alteration in T-PLL have been indicated with gradient colors, respectively (white: no expression, dark gray: high expression). Similarly, physiologic and the illegitimate TRA rearrangements and consequent TRA expression occurring in normal T-cells and T-PLL, respectively, have been indicated by the gradient colors. The TRA-TCL1A fusion most likely occurs in double positive cortical thymocyte stage as highlighted in red. CD4 ISP, CD4+ immature single positive; DP, double positive; EDP, early double positive; ETP, early T-cell precursor; SP, single positive.
Supporting Information Figure 3). The findings in case #8 subjected to WGS independently twice were in complete agreement. Nevertheless, we verified the fusion sequences from WGS by polymerase chain reaction-based Sanger sequencing in 14/17 T-PLL samples (including SUP-T11), excluding the already published cases2 (Supporting Information Tables 3 and 4). We could detect and validate both breakpoints in 11/14 cases and one out of the two breakpoints in the remaining three (cases #6, #10 and #12) (Figure 1B, Supporting Information Table 5). With regard to the fusion sequences in 14q32.1, the breakpoint junctions of 12/13 T-PLL cases carrying an inv(14) were located centromeric of TCL1A (ENST00000554012.1) at a median distance of 41719 bp (range 5745-132339 bps). In the remaining case (#8 or #8a) with inv(14), we observed a breakpoint in exon 4 which disrupted the 3′-untranslated region (3′UTR) of TCL1A. In contrast, the breakpoints of three T-PLL cases with t(14;14) cases mapped 7634-128460 bp telomeric of TCL1A (Figure 1A, Supporting Information Figure 4). Remarkably, both breakpoint clusters of inv(14) and t (14;14) leave only TCL1A as an oncogenic target common to all these changes, as transcriptional units neighboring TCL1A were not consistently juxtaposed to the TRA/TRD enhancers in all cases. In line with the genomic findings, RNA-seq data available in 10 T-PLL cases with inv(14) or t(14;14) showed significantly higher TCL1A transcript levels as compared to benign CD4+ and CD8+ T-cells (P = 0.001, Mann-Whitney test) (Figure 1C, Supporting Information Figure 5). Both breakpoints on Xq28 in the T-PLL case with t(14;14) mapped to intron 1 of MTCP1 (ENST0000036218.2) (Supporting Information Figure 6). MTCP1 overlapped with CMC4 and both were found to be higher expressed in the T-PLL case with t(X;14) as compared to CD4+ and CD8+ benign T-cells (Supporting Information Figure 6).

These genomic and transcriptomic findings corroborate the consistent deregulation of the TCL1A and MTCP1 oncogenes in T-PLL, in line with previous studies.9,10 As juxtaposition of oncogenes to TCR or immunoglobulin (IG) loci by an illegitimate TCR/IG rearrangement is usually supposed to result in deregulated transcription of respective oncogene, it is notable that the physiological expression of TCL1A during T-cell development is observed up to CD4+ immature single positive (CD4 ISP) stage, whereas it is silenced in later stages of T-cell development4-7 (Figure 1D).

To gain further insights into the T-cell maturation stage at which the TCL1A/MTCP1 inversions/translocations occur we investigated the junctional sequences of the illegitimate rearrangements leading to the oncogenic fusions at the TRA/TRD locus in 14q11. We observed that all 17 T-PLL cases (including SUP-T11) have a breakpoint at a recombination signal sequence (RSS) of the J region of TRA (JA) and juxtapose the TRA enhancer (Ea) in cis to the TCL1A/MTCP1 gene(s). In addition, we detected nontemplated (‘N’) nucleotides at the fusion junction of 15/17 cases (Supporting Information Table 5). Moreover, we observed that the breakpoints were more variable on the other side of the inversion/derivative chromosomes: one case breaks at TRAJ58, one case breaks at TRAJ61, seven cases break at a TRAV, one breaks at a hybrid TRAV23/DV6, three break at a TRDV2 segment, one breaks at a TRDD3 and three break between TRAV41 and TRDV2, which are located adjacent to each other. Interestingly, case #9 with a breakpoint in TRDD3 (delta diversity 3) had a second breakpoint in TRAJ61 on the other allele. This JA gene segment is the most proximal to the TRD locus. With the exception of breaks in three cases (#1, #2, #4), also these junctions mapped close to a classical RSS. The breakpoints in these three cases were located between TRAV41 and TRDV2 (Supporting Information Table 5). Two clustered within 10 bp and one was at a distance of approximately 2 kb from the 5′ end of the TRA/D gene cluster, respectively. We searched for the presence of a cryptic RSS at the proximity of the breakpoints between TRAV41 and TRDV2. Using the RSS database CNR-ITB,11,12 we found that case #2 breaks at the junction of cryptic RSS 23 (cRSS-23) and that the case #1 breakpoint is 12 bp upstream of the same cRSS-23, whereas the breakpoint in case #4 is 85 bp upstream of another cRSS-23 (Supporting Information Table 6). These findings strongly suggest involvement of the RAG enzyme, especially in cases #1 and #2, targeting noncanonical RSS found in the region between TRAV41 and TRDV2. Interestingly, both were RSS-23 (rather than RSS-12), which are used by TRAV and TRDV gene segments. Finally, we investigated the expression of the TRD locus on the basis of RNA-seq data. We did not identify significant expression from any of the V(D)J gene segments of the TRD locus in the T-PLL cases. This finding is in agreement with the disruption of the TRD locus as a result of TRA locus rearrangement. Physiological TRD locus rearrangement in T-cell development starts at the early T precursor (ETP) thymic stage. After TRD rearrangement the cell proceeds to the pro and pre T-cell stage and later to the CD4 ISP stage13 (Figure 1D). Our data indicate that the translocation/inversion events involving TCL1A/MTCP1 in T-PLL occur at the point when the TRA locus opens or becomes accessible for VJ rearrangement, which leads to the excision of the TRD locus. This is the stage when the thymocyte proceeds from the double negative pre-T cell stage and develops via CD4 ISP and early double positive (EDP) stage into the double positive (DP) cortical stage of T-cell maturation.13,14 Remarkably, at this stage some physiologic TCL1A expression is likely also maintained before the thymocyte silences the expression of this gene at later stages of T-cell development. As outlined above, oncogene expression is supposed to be a prerequisite for such enhancer hijacking events like inv(14)/t(14;14) in lymphatic neoplasms. Thus, the occurrence of the hallmark event coincides with and prevents physiological down-regulation of TCL1A (Figure 1D).7

The illegitimate TRA/TRD rearrangements in T-PLL prevent expression of a functional TCR alpha or delta in tumor cells from the affected allele. Taking into consideration that T-PLL cells nevertheless not only express a functional T-cell receptor but also seem to rely on that,15-17 we investigated the second allele of chromosome 14 in which the TRA/TRD locus remains unaffected by the cancer-related aberration. As outlined above, we failed to detect significant expression of TRD V and J segments in the analyzed T-PLL cases. Thus, we studied the configuration of the normally rearranged TRAV and TRAJ by investigating the expression at the TRA locus using the RNA-seq data and combining this information with genomic data for the TRA segments expressed in T-PLL cases (Supporting Information methods). Having thus reconstructed the message for the expressed TRA, we compared the usage of TRAV/TRAJ gene segments in the
physiological rearrangement and those detected in the translocations/inversions. In the functional TRA rearrangements, the TRAV/TRAJ gene segments are generally located distal or central, with just a few being located proximal in the locus (Table 1). However, as detailed above, in the illegitimate rearrangements the affected segments are generally proximal with even one case that uses TRDD3 gene segment and the most proximal TRAJ61 gene segment during recombination (Table 1). Remarkably, this difference between the usages of distal/cenral gene segments in normal TRA rearrangements as compared to proximal gene segments in inversions/translocations is significant ($P < 0.05$, Fisher’s exact test) (Supporting Information). These findings suggest that illegitimate TRA/TRD translocations/inversions occur at first opening of the TRA locus and that the T-PLL (primed) cells use the most proximal TRAV/J gene segments. As these do not result in a productive TRA due to the oncogenic aberrations, the TRAV-J rearrangements take place on the other allele involving progressively more distal TRAV/J gene segments, until a productive rearrangement occurs. To assess the functionality of the TRA derived from the physiologic rearrangement of the second allele, we finally investigated this for any mutations in the rearranged TRA gene segments. We found that none of the nucleotides was mutated in TRAV and TRAJ and that the rearranged sequences were in frame; thus, there was no hint for deleterious changes in the expressed TRA (Supporting Information Table 7), in keeping with expression of a surface TRA protein. Hence, we conclude that T-PLL cells express an intact T-cell receptor alpha chain derived from TRA rearrangements taking place after the illegitimate TRA rearrangement resulting in oncogenic activation.

As the T-PLL (primed) cell is obviously able to further recombine its TCR, we wondered whether traces of this process can be observed in T-PLL. To this end, we investigated the available RNA-seq data for expression of the members of the RAG complex (RAG1 and RAG2) in line with previous data, we found that the T-PLL cases investigated and carrying the hallmark aberrations are devoid of RAG1 (mean expression of 0.1 fpkm, range 0-0.1), RAG2 (mean expression of 0 fpkm, range 0-0) and DNTT (mean expression of 0 fpkm, range 0-0) gene expression. The latter codes for terminal deoxynucleotide transferase (TdT), which is widely expressed in ALL.

### Table 1

| Allele               | Case   | Gene segment | Deleted nucleotides | Localization of gene segment | Gene segment | Deleted nucleotides | Localization of gene segment |
|---------------------|--------|--------------|---------------------|-----------------------------|--------------|---------------------|-----------------------------|
| Normal allele       | Case #1 | TRAV1-2      | 0                   | Distal ++                    | TRAJ18       | 4                   | Distal                      |
|                     | Case #2 | TRAV22       | 5                   | Central                      | TRAJ48       | 0                   | Central                     |
|                     | Case #6 | TRAV14DV4*   | 9                   | Central/distal               | TRAJ29       | 4                   | Central                     |
|                     | Case #7 | TRAV12-2     | 3                   | Distal                       | TRAJ42       | 3                   | Central                     |
|                     | Case #8 | TRAV6        | 1                   | Distal                       | TRAJ43       | 1                   | Proximal/central             |
|                     | Case #9 | TRAV12-1     | 1                   | Distal                       | TRAJ13       | 0                   | Distal                      |
|                     | Case #10| TRAV29DV5*   | 3                   | Proximal/central             | TRAJ10       | 4                   | Distal                      |
|                     | Case #11| TRAV8-6      | 0                   | Central/distal               | TRAJ11       | 7                   | Distal                      |
|                     | Case #12| TRAV12-1     | 0                   | Distal                       | TRAJ31       | 5                   | Central                     |
|                     | Case #13| TRAV9-2      | 4                   | Central/distal               | TRAJ9        | 4                   | Distal                      |
|                     | SUP-T11 | TRAV25       | 5                   | Central                      | TRAJ40       | 2                   | Central                     |
| Inverted/translocated allele | Case #1 | TRAV41DV2*   | 0                   | Proximal ++                  | TRAJ58       | 2                   | Proximal ++                 |
|                     | Case #2 | TRAV41DV2*   | 0                   | Proximal ++                  | TRAJ61       | 0                   | Proximal ++                 |
|                     | Case #6 | TRAV38-1     | 2                   | Proximal                     | TRAJ52       | 8                   | Proximal                    |
|                     | Case #7 | TRAV23DV6*   | 1                   | Central                      | TRAJ46       | 2                   | Proximal                    |
|                     | Case #8 | TRAV39       | 3                   | Proximal                     | TRAJ49       | 0                   | Proximal                    |
|                     | Case #9 | TRDD3        | 1                   | TRDD3                        | TRAJ61       | 0                   | Proximal ++                 |
|                     | Case #10| TRAV35       | 15                  | Proximal                     | TRAJ28       | 1                   | Central                     |
|                     | Case #11| TRAV21       | 3                   | Central                      | TRAJ23       | 10                  | Central                     |
|                     | Case #12| TRAV10       | 8                   | Distal                       | TRAJ31       | 11                  | Central                     |
|                     | Case #13| TRAV8-4      | 15                  | Distal                       | TRAJ17       | 8                   | Distal                      |
|                     | SUP-T11 | TRAV22       | 3                   | Central                      | TRAJ42       | 18                  | Proximal/central             |

Note: #: V gene segment shared between TRA and TRD; Localization of gene segment: Localization of the rearranged gene segment within the TRAV or TRAJ locus, proximal TRAV: proximal gene segment to TRAJ, distal TRAV: distal gene segment to TRAJ; proximal TRAJ: proximal gene segment to TRAV, distal TRAJ: distal gene segment to TRAV, distal ++: very distal TRAV/TRAJ gene segments.
but not T-PLL. We thus conclude that in T-PLL, the genes involved in TRA recombination are activated while the illegitimate TRA VJ rearrangement occurs, remain active during several rounds of recombination until the T-cell achieves its functional rearranged TRA and are switched off thereafter (Figure 1D).

In the present study, using WGS-based and breakpoint analysis of physiologic and illegitimate TRA rearrangements combined with whole transcriptomic expression profiling we have identified the potential time-point when the hallmark oncogetic event in T-PLL occurs. We have shown that T-cells in T-PLL go through normal early stages of thymocyte development where physiologic rearrangements of TCR gamma, delta and beta gene rearrangements take place in the early T precursor (ETP), pro and pre-T cell stage, respectively. When the cell reaches the double positive (DP) stage at which the TRA locus becomes accessible, an illegitimate TRA rearrangement takes place as a result of an inversion/translocation activating the oncogenes TCL1A/MTCP1. At this stage, the thymocyte subsequently goes through multiple rounds of TRA rearrangements in the presence of RAG enzymes until it undergoes a rearrangement which produces a functional TCR alpha chain that is required by the T-PLL cells to survive and proliferate. Thereafter, the poised T-PLL cell seems to be able to progress through T-cell maturation steps including switching off its RAG machinery. These observations also reflect a requirement for TCR expression in T-PLL, since these leukemias could formally have a cortical thymic, sCD3 negative phenotype, with no surface TCR expression, if TCL1 driven oncogenesis were sufficient for leukemic development in the absence of TCR expression. This is similar to the requirement for TCR expression in NPM-ALK driven anaplastic large cell lymphoma.20 In contrast, TCL1-TCR rearrangements in (mainly sTCR negative) T-ALL are extremely rare and virtually never involve TRA.21

Thus, the present study provides detailed insights into the sequential genomic alterations that lead to and follow from hallmark oncogenic event in T-PLL. Nevertheless, it needs to be emphasized that our study does not claim that these are the "initial" steps of T-PLL pathogenesis, as this would require chronologic alignments of illegitimate TRA rearrangements with ATM mutations, since the latter occur in the vast majority of T-PLL.7,22 The increased incidence of T-PLL in patients with germline mutations in ATM23 and the function of the ATM protein in repair of RAG-mediated DNA breaks might suggest that ATM dysfunction, whether encoded by germline or somatic genetic changes or due to stochastic alterations in expression, might contribute to the occurrence of illegitimate TRA rearrangements in T-PLL.17,24 This would suggest a model in which ATM alterations take place before TRA rearrangements in T-PLL, which needs to be tested in future studies.

ACKNOWLEDGMENTS
We would like to thank the FACS core facility of Ulm University for their contribution in the experiments. We thank the members of the cancer genetics laboratories of the Institutes of Human Genetics in Ulm and formerly Kiel for expert support in cytogenetic and molecular cytogenetic studies. We gratefully acknowledge contributing centers for enrolling all patients. We thank the Omics IT and Data Management Core Facility of the German Cancer Research Center (DKFZ) for excellent technical support.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES
1. Swerdlow SH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017.
2. Herling M, Khoury JD, Washington LT, Durvic M, Keating MJ, Jones D. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004;104(2):328-335.
3. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91(26):12530-12534.
4. Hoyer K, Herling M, Bagrintseva K, et al. T cell leukemia-1 modulates TCR signal strength and IFN-γ levels through phosphatidylinositol-3-kinase and protein kinase C pathway activation. J Immunol. 2005;175(2):864-873.
5. Pekarsky Y, Hallas C, Croce CM. The role of TCL1 in human T-cell leukemia. Oncogene. 2001;20(40):5638-5643.
6. Roth DB. VDJ recombination: mechanism, errors, and fidelity. Microbiol Spectr. 2014;2(6):313-324.
7. Schrader A, Crispaztu G, Oberbeck S, et al. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018;9(1):697.
8. Smith SD, McFall P, Morgan R, et al. Long-term growth of malignant thymocytes in vitro. Blood. 1989;73(8):2182-2187.
9. Bug S, Dürig J, Oyen F, et al. Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia. Blood. 2016;127(20):2597-2605.
10. Thick J, Metcalfe JA, Mak YF, et al. Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients. Oncogene. 1996;12(2):379-386.
11. Cowell LG, Davila M, Kepler TB, Kelsoe G. Identification and utilization of arbitrary correlations in models of recombination signal sequences. Genome Biol. 2002;3(12):RESEARCH0072.
12. Cowell LG, Davila M, Ramsden D, Kelsoe G. Computational tools for understanding sequence variability in recombination signals. Immunol Rev. 2004;200:57-69.
13. Dik WA, Pike-Overzet K, Weerkamp F, et al. New insights on human T cell development by quantitative T cell receptor gene rearrangement analysis and confirms clonality in all T-cell prolymphocytic leukemia cases. Cytometry A. 2018;93(11):1118-1124.
17. Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. *Blood*. 2008;111(1):328-337.

18. Sadofsky MJ. The RAG proteins in V(DJ) recombination: more than just a nuclease. *Nucleic Acids Res*. 2001;29(7):1399-1409.

19. Fugmann SD, Lee AI, Shockett PE, Villey IJ, Schatz DG. The RAG proteins and V(DJ) recombination: complexes, ends, and transposition. *Annu Rev Immunol*. 2000;18:495-527.

20. Malcolm TIM, Villarese P, Fairbairn CJ, et al. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. *Nat Commun*. 2016;7:10087.

21. Sugimoto K-J, Shimada A, Wakahayashi M, et al. T-cell lymphoblastic leukemia/lymphoma with t(7;14)(p15;q32) [TCRγ-TCL1A translocation]: a case report and a review of the literature. *Int J Clin Exp Pathol*. 2014;7(5):2615-2623.

22. Stankovic T, Taylor AM, Yuille MR, Vorechovsky I. Recurrent ATM mutations in T-PLL on diverse haplotypes: no support for their germline origin. *Blood*. 2001;97(5):1517-1518.

23. Stilgenbauer S, Schaffner C, Litterst A, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. *Nat Med*. 1997;3(10):1155-1159.

24. Yamaguchi M, Yamamoto K, Miki T, Mizutani S, Miura O. T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency. *Cancer Genet Cytogenet*. 2003;146(1):22-26.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Patil P, Cieslak A, Bernhart SH, et al. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. *Genes Chromosomes Cancer*. 2020;59:261–267. [https://doi.org/10.1002/gcc.22821](https://doi.org/10.1002/gcc.22821)